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ABSTRACT The increasing antibiotic resistance of pathogenic Escherichia coli species and the absence of a pan-protective vaccine
pose major health concerns. We recently identiﬁed, by subtractive reverse vaccinology, nine Escherichia coli antigens that pro-
tect mice from sepsis. In this study, we characterized one of them, ECOK1_0290, named FdeC (factor adherence E. coli) for its
ability to mediate E. coli adhesion to mammalian cells and extracellular matrix. This adhesive propensity was consistent with the
X-ray structure of one of the FdeC domains that shows a striking structural homology to Yersinia pseudotuberculosis invasin
and enteropathogenic E. coli intimin. Confocal imaging analysis revealed that expression of FdeC on the bacterial surface is trig-
gered by interaction of E. coli with host cells. This phenotype was also observed in bladder tissue sections derived from mice in-
fectedwithanextraintestinalstrain.Indeed,weobservedthatFdeCcontributestocolonizationofthebladderandkidney,with
thewild-typestrainoutcompetingthe fdeCmutantincochallengeexperiments.Finally,intranasalmucosalimmunizationwith
recombinant FdeC signiﬁcantly reduced kidney colonization in mice challenged transurethrally with uropathogenic E. coli, sup-
portingaroleforFdeCinurinarytractinfections.
IMPORTANCE Pathogenic Escherichia coli strains are involved in a diverse spectrum of diseases, including intestinal and extraint-
estinal infections (urinary tract infections and sepsis). The absence of a broadly protective vaccine against all these E. coli strains
isamajorproblemformodernsocietyduetohighcoststohealthcaresystems.Here,wedescribethestructuralandfunctional
propertiesofarecentlyreportedprotectiveantigen,namedFdeC,andelucidateditsputativeroleduringextraintestinalpatho-
genic E. coli infection by using both in vitro and in vivo infection models. The conservation of FdeC among strains of different
E. coli pathotypes highlights its potential as a component of a broadly protective vaccine against extraintestinal and intestinal
E. coli infections.
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E
scherichia coli strains are versatile microorganisms that con-
stantly acquire and lose virulence attributes, leading to the
emergenceofsuccessfulnewgeneticcombinationsthatcanconfer
an increased ability to colonize new niches and to cause a broad
spectrumofintestinalandextraintestinaldiseases(1).Strainswith
successfulcombinationsofvirulencefactorsandthatcausesimilar
diseaseshavebecomepathotypes.IntestinalE.colipathotypesap-
pear to be unable to persist in the human intestine and cause
diarrheal diseases only when ingested in sufﬁcient quantities by a
naive host. On the other hand, extraintestinal pathogenic E. coli
(ExPEC), while not inducing enteric disease, can asymptomati-
cally colonize the human intestinal tract as the predominant spe-
cies in ~20% of healthy individuals (2, 3). Extraintestinal infec-
tions resulting from these strains, however, include neonatal
meningitis, urinary tract infections (UTIs), diverse intra-
abdominal infections, pneumonia, intravascular-device infec-
tions, osteomyelitis, soft tissue infections, bacteremia, and sepsis
(4). In particular, UTIs, which can be either asymptomatic or
symptomatic, are characterized by a wide spectrum of manifesta-
tions ranging from mild dysuria to bacteremia, sepsis, or even
death (5). Uncomplicated UTI is conﬁned to the bladder, while
severely complicated UTIs include pyelonephritis and urosepsis.
Recurrent UTIs occur as result of reinfection by bacteria from
outsidetheurinarytractorfrompersistentbacteria(6).Virulence
factors most commonly associated with uropathogenic E. coli
(UPEC) include adhesive ﬁmbriae, iron acquisition systems, and
toxins such as hemolysin and cytotoxic necrotizing factor (7). Af-
ter bacterial attachment, UPEC may invade epithelial cells and
form small clusters of intracellular bacteria, termed intracellular
bacterial communities (IBCs) (8). Bacteria may persist in these
protective niches, creating a chronic quiescent reservoir in the
bladder.
UPECstrainscontributesigniﬁcantlytotheburdenofExPEC-
associated diseases, being the causative agent in 70% to 95% of
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infections (9). Due to the emergence of an increasing number of
antibiotic-resistant strains, the development of an efﬁcacious Ex-
PEC vaccine would have both a signiﬁcant impact on public
health and great economic beneﬁt. Recently, we determined the
genome sequence of an ExPEC K1 strain, IHE3034 (ST95), iso-
lated from a case of neonatal meningitis, and compared it to the
availablegenomesequencesofotherExPECstrainsandafewnon-
pathogenicE.colistrains(10).Byasubtractivereversevaccinology
approach, nine antigens were identiﬁed and demonstrated to be
protectiveinamousemodelofsepsis.Theirconservationinother
E.colipathotypesindicatedtheirpotentialascandidatesforauni-
versalE.colivaccine(10).Inthisreport,wedescribethestructural
and functional properties of one of these protective antigens,
ECOK1_0290,renamedFdeC(forfactoradherenceE.coli).Inthis
analysis, we elucidated its putative role during ExPEC pathogen-
esis by using both in vitro and in vivo infection models. Our ﬁnd-
ings, corroborated by epidemiological data on antigen conserva-
tioninotherpathotypes,stronglysupporttheimportanceofFdeC
in E. coli colonization of host tissues and the relevance of the
protein as a vaccine target.
RESULTS
Genomic characterization, distribution, and conservation of
the fdeC gene. FdeC, previously annotated in the ExPEC strain
IHE3034 as bacterial immunoglobulin-like domain (group 1)
protein (ECOK1_0290) (10), is a 1,416-amino-acid (aa) protein
that has low sequence similarity with Yersinia pseudotuberculosis
invasin (11) and enteropathogenic E. coli (EPEC) intimin (12)
(conserved up to 35% over selected regions). In addition, FdeC
shares 95% identity with EaeH, a putative adhesin identiﬁed by
subtractive hybridization from the genome sequence of the en-
terotoxigenic E. coli (ETEC) strain H10407 (13). A closer exami-
nation of the region encompassing the fdeC gene showed that in
ExPEC strains (Fig. 1) and other E. coli pathotypes (see Fig. S1 in
the supplemental material) the gene resides in a locus containing
up to three putative regulatory genes and ﬁve putative reductases
and hydrolases. In the nonpathogenic K-12 strains, the fdeC gene
isdisruptedandispresentasashorterpseudogene,corresponding
only to the N-terminal region of the full-length protein (Fig. 1).
To assess the distribution of the fdeC gene among different E. coli
isolates, we evaluated the prevalence of the gene in 128 sequenced
E. coli genomes available in public databases and performed PCR
ampliﬁcation of the gene in a collection of 143 E. coli isolates,
including distinct pathotypes of human and animal origin. The
fdeC gene was found to be highly distributed among all strains
with an overall presence of approximately 99% in ExPEC isolates
and 92 to 100% in intestinal E. coli pathotypes (Table 1). When
present, the gene is highly conserved with 91% identity at the
amino acid sequence level among these strains.
Sequence organization and crystal structure of FdeC. Se-
quenceanalysisrevealedthatFdeCispredictedtocontainanum-
ber of bacterial Ig-like domains. The N-terminal region is identi-
ﬁed as a domain of unknown function (DUF3442) and is likely to
form a -barrel multidomain structure. Considering this predic-
tion and the inability to purify soluble full-length recombinant
protein, FdeC was divided into three regions: region A, predicted
as the transmembrane domain, and regions B and C, predicted to
contain the extracellular Ig-like domains (Fig. 2A). While no ex-
pressionwasobtainedforregionAalone,wesuccessfullypuriﬁed
solublerecombinantpolypeptidesforthefollowingfragments:AB
(FdeCAB), B (FdeCB), and C (FdeCC). Fragment C, however, was
unstable and rapidly degraded postpuriﬁcation.
Among these fragments, we solved the crystal structure of re-
gion B (residues 597 to 1008), previously reported to be responsi-
ble for the antigenic properties of the protein (10). The FdeCB
crystal structure was solved at 1.9-Å resolution. Electron density
could be identiﬁed only for residues 678 to 991 of the structure,
and crystal packing showed no space available to contain the ﬁrst
81 residues of the construct, leading us to conclude that these
FIG 1 Comparative genome analysis of the fdeC cluster. Graphical representation of the fdeC cluster, containing the fdeC gene (red), putative transcriptional
regulators (blue), putative reductases and hydrolases (green), insertion sequences, and variable genes (gray). Regions highly conserved among all the strains are
considered core regions (black). Truncated genes are represented in light colors. Linear visualization of the fdeC cluster was generated by a noncommercial
software program for research purposes, GECO (36). NMEC, neonatal meningitis-associated E. coli.
TABLE 1 fdeC gene distribution analysis
Pathotypea No. positive Total no. Prevalence, %
ExPEC 116 117 99.1
ETEC 13 14 92.9
EHEC 34 38 89.5
EPEC 5 5 100.0
AIEC 3 3 100.0
EAEC 3 3 100.0
STEC 6 6 100.0
Other 53 55 96.4
Commensal/fecal 19 23 82.6
Nonpathogenic 2 7 28.6
a The fdeC gene presence was evaluated in 128 sequenced genomes (based on 90%
identity) and in 143 clinical isolates by PCR ampliﬁcation. ExPEC, avian pathogenic
E. coli; UPEC, uropathogenic E. coli; NMEC, neonatal meningitis-associated E. coli;
SEPEC, septicemic E. coli; ETEC, enterotoxigenic E. coli; EHEC, enterohemorrhagic
E. coli; EPEC, enteropathogenic E. coli; AIEC, adherent-invasive E. coli; EAEC,
enteroaggregative E. coli; STEC, Shiga toxin-producing E. coli; other, unknown
pathotypes; commensal/fecal, E. coli isolated from healthy individuals; nonpathogenic,
E. coli lab strains.
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radation event. The structure of residues 678 to 991 revealed an
elongated molecule of 126 Å in length and the presence of three
bacterial Ig-like domains, each of 120 amino acids in length
(Fig. 2B), similar to invasin (14). Adopting the domain nomen-
clature of Hamburger et al. (14), numbering the invasin domains
D1toD5fromtheNtotheCtermini,thecomparisonwithinvasin
(Protein Data Bank identiﬁcation [PDB ID] 1CWV) showed that
241 out of the 319 C atoms in the FdeCB fragment aligned with
invasin (PDB_ID 1CWV) with a root mean square deviation
(RMSD) of 2.67 Å. This corresponds to alignment with domains
D2 to D4 of invasin (Fig. 2C and D). Enteropathogenic E. coli
intimin (PDB_ID 1F00) aligns with the FdeCB structure for 139
out of the 282 C atoms with an RMSD of 2.9 Å (Fig. 2C and D).
In the C-terminal portion of both invasin and intimin, a domain
D5, which is a C-type lectin-like moiety that is closely connected
to the D4 domain, is present. In both intimin and invasin, this
domain plays an important role in bacterial binding to their re-
spective receptors. Sequence analysis and modeling of the FdeC
structure revealed no evidence of a C-type lectin domain
(Fig. 2D).
Recombinant FdeCAB binds to human epithelial cells. Based
on the presence of structural features typical of bacterial surface
determinants interacting with host cells, we evaluated the in-
trinsic capacity of FdeC to bind to human bladder (UM-UC-3)
and urethral epithelial (tUEC) cells. We used an antibody-based
indirect immunoﬂuorescence detection system supported by
ﬂuorescence-activated cell sorting (FACS) analysis (see Materials
and Methods) to compare the adhesive properties of the two sol-
uble fragments obtained, FdeCAB and FdeCB. Recombinant Fde-
CAB bound to both UM-UC-3 and tUEC cells (Fig. 3A), reaching
a plateau at a concentration of 106 M. The binding constant
(Kd)valuewascalculatedastheFdeCABconcentrationresultingin
saturationof50%oftheputativereceptorspresentonthecellsand
was estimated to be on the order of 107 M. Recombinant Fde-
CAB also bound to ovary (CHO), cervix (HeLa), and kidney
(Vero) epithelial cell lines (see Fig. S2 in the supplemental mate-
rial). In contrast, FdeCB did not bind to human cells (data not
shown),suggestingtheimportanceoftheAregioninmaintaining
the molecule in a functional conformation. Epithelial cells pro-
duce a speciﬁc array of extracellular matrix (ECM) proteins that
have a fundamental role in maintaining tissue integrity. To inves-
tigatethepropensityofFdeCABtoalsointeractwithselectedECM
components, we performed in vitro binding assays using ﬁbrino-
gen, ﬁbronectin, laminin, and various types of collagen as target
molecules.Bindingwasdetectedusingpolyclonalanti-FdeCanti-
serum and quantiﬁed by enzyme-linked immunoabsorbent assay
(ELISA). Recombinant FdeCAB showed a pronounced dose-
dependent binding to collagen types I, III, V, and VI, with an
estimated Kd on the order of 108 M (Fig. 3B). No binding was
observedtootherECMcompounds,suchasﬁbrinogen,ﬁbronec-
tin, laminin, and collagen IV (data not shown).
ExpressionofFdeCisinducedbyinteractionwithhostcells.
Sinceseveralattemptstoreproduceurinarytractorintestinalcon-
ditions in vitro did not result in native FdeC expression on the
bacterialsurface(seethesupplementalmaterial),wehypothesized
FIG 2 FdeC regions and crystal structure. (A) Schematic of the regional organization of FdeC. (B) Ribbon diagram of FdeCB (amino acids 678 to 991); N and
Cterminiareindicated.(C)SuperimpositionofFdeCB,inblue,withintimin(PDB_ID1F00),inpurple,andinvasin(PDB_ID1CMV),ingreen.(D)Structural
comparisonbetweenthecrystalstructuresofthesurface-exposeddomainsofintiminandinvasinwithamodelofthepotentialsurface-exposedregionofFdeC.
Modeled regions are colored in red, while the crystal structure of FdeCB is colored in blue.
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cells. Using confocal immunoﬂuorescence microscopy, we exam-
ined the expression of FdeC in ExPEC strain IHE3034 (Fig. 4A)
following contact with human uroepithelial cells. We observed
that FdeC was expressed by the bacterial population that was
tightly associated with the plasma membrane of the mammalian
cell,asvisualizedbyF-actinstaining.Similarresultswereobtained
usingtheuropathogenicstrainCFT073(datanotshown).Noﬂu-
orescent signal was observed when infections were carried out
using the fdeC deletion mutant strains (Fig. 4B). These data sug-
gestthatFdeCsurfaceexpressionmaydependonsensingorbind-
ingtohostcells.ToaddressthekineticsofFdeCexpressionduring
interaction with host cells, we performed infection experiments
andcomparedtheappearancesoftheFdeCsignalsonthebacterial
surface at 15, 30, 45, 60, 90, 120, 180, and 240 min. Confocal
imaging analysis of IHE3034, 536, and CFT073 strains in contact
withuroepithelialcellsrevealedthattheswitchingofFdeCexpres-
sion did not occur earlier than 60 min from bacterial loading and
that the proportion of bacteria expressing the protein remained
constantupto4h(datanotshown).FdeCdeletionmutantstrains
were used as internal controls. Quantitative association assays
were performed using IHE3034, 536, and CFT073 strains. Infec-
tion of UM-UC-3 cells at different time points (ranging from
15 min to 4 h) revealed no signiﬁcant differences in the CFU
counts between wild-type and respective isogenic fdeC mutant
strains (data not shown). These data suggest that in this in vitro
system, constitutively expressed adhesins mask the contribution
of FdeC to bacterial adhesion.
ConstitutiveexpressionofFdeCresultsinbacterialaggrega-
tion. To better evaluate the contribution of FdeC to adhesion, we
engineered the well-characterized, weakly adhesive E. coli K-12
strain W3110 (naturally devoid of the fdeC gene) for constitutive
FIG 3 Binding of recombinant FdeC to epithelial cells and ECM. (A) UM-UC-3 and tUEC cells were incubated for1ha t4 ° Cwith increasing concentrations
of recombinant FdeCAB. Binding of FdeCAB to cells was assessed by ﬂow cytometry, and data are shown as mean ﬂuorescence intensity (MFI) values plotted in
the saturation curves. (B) Binding of increasing concentrations of FdeCAB to collagen I, III, V, and VI (open circles). BSA is used as a negative control (solid
circles). Binding was quantiﬁed by ELISA. Points represent the means (error bars show standard errors of the means) of measurements made in triplicate.
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proteinonthesurfaceoftheW3110::fdeCstrainwasconﬁrmedby
electronmicroscopyanalysis(Fig.5A).Assaysoftheadherenceof
W3110wild-typeandW3110::fdeCstrainstohumanbladderUM-
UC-3 cells, quantiﬁed using viable CFU counts (Fig. 5B) and by
confocal microscopy (Fig. 5C), clearly showed the strong contri-
bution of FdeC in the adherence of E. coli to epithelial cells. How-
ever, gentamicin protection assays reveal a low invasion of UM-
UC-3cellsbytheW3110::fdeCstrain(datanotshown).Theuseof
E.coliK-12anditsderivativesasamodeltoassessbacterialattach-
ment to solid surfaces has been established previously (15). By
comparing the W3110 wild-type and W3110::fdeC strains, we ob-
FIG 4 Confocal analysis of FdeC expression in contact with cultured epithelial cells. Monolayers of UM-UC-3 cells were infected with IHE3034 (A) and the
respectivefdeCknockoutmutantstrain(B).Attheendoftheinfection,thesampleswereﬁxedandstainedforconfocalimmunoﬂuorescencemicroscopy.FdeC
was detected using speciﬁc antibodies and visualized using a ﬂuorescent secondary antibody (green). DAPI was used to stain the host cell nuclei and visualize
bacteria (blue). Cellular actin was stained with ﬂuorescent phalloidin (red).
FIG 5 Constitutive surface exposure of FdeC in strain W3110::fdeC induces the formation of bacterial aggregates. (A) Immunogold transmission electron
microscopyofFdeCsurfacelocalizationinW3110wild-type(leftpanel)andW3110::fdeC(rightpanel)strains.Fixedbacteriawereincubatedwithananti-FdeC
serumandthenwiththesecondaryantibodieslabeledwith10-nmgoldparticles.Bars,200nm.(B)AssociationrateofW3110andW3110::fdeCwithUM-UC-3
cells.TheW3110(whitebar)andtheW3110::fdeC(graybar)strainswereusedtoinfectUM-UC-3monolayersfor3hatamultiplicityofinfectionof10:1.Viable
cell-associated bacteria were quantiﬁed after cell lysis. Results are expressed as a percentage of the inoculum. The data displayed illustrate the results of three
independent experiments, including standard deviations. (C) Confocal microscopy analysis of UM-UC-3 cells infected with W3110 wild-type (left panel) and
W3110::fdeC (right panel) strains. The W3110 strain and its derivative were detected using a polyclonal rabbit anti-E. coli K-12 antibody (green ﬂuorescence).
Actin was stained in red using phalloidin. (D) Confocal images of W3110 wild-type (left panel) and W3110::fdeC (right panel) strains adhering to glass slides
reveal the propensity of the FdeC-expressing strain to form aggregates. Bacteria were localized with DAPI (blue), and FdeC was detected using the anti-FdeC
serum and a ﬂuorescent secondary antibody (red). (E) In vitro microcolony formation by W3110 (left) and W3110::fdeC (right) strains grown in LB medium at
RT in polystyrene tubes. The macroscopic aggregates were visualized by crystal violet staining. (F) Kinetics of microcomplex formation at up to 6 days.
Quantitative crystal violet staining was used to measure the level of the aggregation for W3110::fdeC in comparison with the W3110 wild-type strain. Data
represent means and standard deviations of three independent measurements.
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gregates on glass slides (Fig. 5D). ExPEC species are known to use
anumberofsurface-associateddeterminantstoforminvivomac-
rocommunities, often deﬁned as bioﬁlms (16). In particular, sev-
eral studies have indicated the important role of bioﬁlms in UTIs,
notablyincatheterizedpatients(17,18).Usingapreviouslyestab-
lished protocol for determining the propensity of E. coli strains to
form aggregates in vitro (19), we demonstrated that, compared to
the wild-type control, the W3110::fdeC strain is able to strongly
interact with solid surfaces and produce macrocomplexes when
grown in polystyrene tubes (Fig. 5E). The capacity of the W3110::
fdeC strain to form bacterial aggregates was monitored up to
6 days and quantiﬁed by crystal violet staining (Fig. 5F).
FdeC contributes to colonization of the urinary tract. In or-
dertodetermineifFdeCplaysaroleinvirulence,weperformedan
independent challenge experiment in mice infected with wild-
type E. coli 536 and its isogenic fdeC mutant strain. As shown in
Fig. 6A, confocal immunoﬂuorescence microscopy of parafﬁn-
embedded bladder sections revealed that FdeC is speciﬁcally ex-
pressed by wild-type bacteria closely associated with the bladder
tissue and that the number of bacteria was signiﬁcantly higher
than that in tissue derived from mice inoculated with the fdeC
mutant strain (Fig. 6B). Imaging data were representative of a
qualitativeimaginganalysisof10bladdersectionsthatcollectively
revealed reduced bladder colonization by the mutant strain. To
evaluate the contribution of FdeC to bacterial ﬁtness in vivo dur-
ing colonization of the urinary tract, female CBA/J mice were
transurethrally inoculated with a 1:1 ratio of E. coli 536 and the
fdeC, kanamycin-resistant, knockout mutant. At 48 h postinocu-
lation, bacteria from tissue homogenates were prepared in the
presence of 0.1% saponin to separate eventual aggregates. Live
bacteria were enumerated by viable counts. Bacterial ﬁtness was
determined as competitive index (CI) for cochallenge data. We
observedthatdeletionoffdeCfromstrain536causedasigniﬁcant
reductioninﬁtnessduringUTIinboththebladderandthekidney
(Fig.6C).Thesigniﬁcantdifferencebetweenthemutantandwild-
type colonization levels indicated that FdeC may have an impor-
tant role in E. coli ﬁtness during an ascending urinary tract infec-
tion.
Vaccination with recombinant FdeC confers protection
against ExPEC during experimental UTI. Since FdeC
(ECOK1_0290)wasamongthenineantigensshowntobeprotec-
tiveinamousemodelofsepsis(10)andshownheretocontribute
to virulence, we decided to test whether the antigen could also
induce protection in the murine model of ascending UTI. To-
wards this end, FdeCB was mixed with the adjuvant cholera toxin
(CT)ataratioof10:1(antigentoCT)andgroupsofmice(n30)
were intranasally inoculated with either the antigen-CT mixture
or CT alone. Following primary immunization (day 0) and
booster doses (days 7 and 14), animals were transurethrally chal-
lenged with the UPEC strain 536 and protection was assessed at
48 h postinfection by determining CFU in the urine, bladder, and
kidneys.FdeCBinducedsigniﬁcantprotectioninthekidneywitha
1.5-log reduction in median CFU/g (P value  0.0067) (Fig. 7A).
Inaddition,17/30vaccinatedmicehadundetectablelevelsofbac-
teriainthekidney(102CFU/gtissue).Wealsoobservedastrong
trend in reduction of kidney colonization after challenge with the
UPEC strain CFT073, with a 2.5-log reduction in median CFU/g
(Fig. 7B). In this case, 50% of mice had undetectable levels of
bacteria (102 CFU/g tissue) in the kidney. This demonstrated
that mucosal immunization in the nares generates a protective
effect at distal sites. These data strongly support the use of FdeCB
as a component in a vaccine able to prevent all ExPEC-associated
diseases.
DISCUSSION
The development of an efﬁcacious, broadly cross-protective vac-
cine against most E. coli pathotypes would have signiﬁcant public
health and economic beneﬁts, considering the increasing antibi-
otic resistance among E. coli strains and the associated mortality,
morbidity, and lost productivity. We have recently compared
available genome sequences of different E. coli strains, and by us-
ing a subtractive reverse vaccinology approach, we identiﬁed a
number of antigens common to different pathotypes, capable of
inducing protection in a mouse model of sepsis, thus proposing
their use for the development of a universal E. coli vaccine (10).
Bioinformatic analysis of one of these antigen candidates, here
named FdeC, revealed an interesting structural similarity with in-
FIG6 RoleofFdeCinvivoinamodelofascendingUTI.ConfocalimaginganalysisofFdeCexpressioninbladderfrommiceindependentlyinfectedwithUPEC
wild-typestrain536(A)andtheisogenicfdeCmutantstrain(B).TissuesectionsembeddedinparafﬁnwerestainedwithWGAconjugatedwithAlexaFluor647
(blue), while UPEC strain 536 was detected using a polyclonal serum raised against inactivated whole bacteria (red). FdeC was stained in green. The images are
representative of multiple observations, from at least 10 sections. (C) Cochallenge experiments using the 536 wild-type strain and the fdeC isogenic knockout
mutant. In vivo competitive indices (CI) were determined following cochallenge infections of female CBA/J mice with a 1:1 ratio of wild-type 536 and fdeC
knockout mutant strains. At 48 h postinoculation, bacteria were enumerated by plating serial dilutions from tissue homogenates. The CI from each tissue was
determinedbydividingthemutant-to-wild-typeratioofCFU/gbythemutant-to-wild-typeratioofCFUfromthemixedinoculum.Eachdotrepresentsbladders
and kidneys from an individual animal. Bars indicate the median CI. Signiﬁcant differences in colonization (*) (P values, 0.05) were determined by the
Wilcoxon signed rank test. A CI of 1 indicates a ﬁtness defect.
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hostcells.Inparticular,theFdeCregionB(FdeCB)ispredictedto
have the same arrangement of four bacterial immunoglobulin
foldsasdoestheY.pseudotuberculosisinvasinstructure.TheX-ray
structure of FdeCB conﬁrmed this structural homology, with the
truncated form of FdeCB (678 to 991 amino acids [aa]) sharing
both the immunoglobulin fold arrangement and the quaternary
structure of invasin (14).
SincethefdeCgeneispresentindifferentE.colipathotypesand
has structural similarity to other pathogenic adhesion molecules,
we hypothesize that FdeC could contribute to virulence, as an
adhesin essential for infection in the host. In UPEC strains, for
instance, adhesion is vitally important to overcome host defenses
in the urinary tract and resist the ﬂushing effect of the urine. The
role of FdeC in E. coli colonization of host tissues was supported
notonlybyinvivoevidenceshowingdecreasedbacterialﬁtnessof
thefdeCmutantstrainduringexperimentalurinarytractinfection
but also by the fact that the recombinant FdeC binds with strong
afﬁnitytoseveralepithelialcelllinesandthatitssurfaceexpression
on the bacteria is host cell contact dependent. In addition, its
capacity to bind different collagen types, including type V and VI
(bothwidelyexpressedintheinterstitialspaceofkidneyandblad-
der), strongly supports the hypothesis for a speciﬁc role of FdeC
during bacterial colonization.
Genome comparison of the loci containing the fdeC gene in
differentE.colistrainsrevealedthatitispresentasapseudogenein
the nonpathogenic K-12 E. coli strains, such as MG1655, W3110,
and DH10B. However, in human commensal E. coli isolates, HS
andSE11,andinmanyfecalstrains,thefull-lengthfdeCispresent,
indicatingthattheproteinmightbefunctionalandprovideagen-
eral advantage during host colonization. For example, E. coli HS
hasbeenshowntostablycolonizethehumangastrointestinaltract
but cause no detectable disease or adverse effects (20). On the
otherhand,strainSE11,acommensalE.coliisolatefromthefeces
of a healthy human adult, evolved to acquire and accumulate the
functions advantageous for stable colonization of intestinal cells
(21). It possesses more genes involved in adhesion than does the
K-12 strain MG1655, which is no longer able to colonize the hu-
man gut.
In general, the biogenesis of bacterial adhesive structures is a
tightly controlled process. The cost in energy and other resources
required for expression of an adhesin must be balanced with any
potential beneﬁts that a particular adhesive organelle might pro-
vide to a bacterium. Variable expression of different adhesive or-
ganelles, such as ﬁmbriae, may allow the bacterium to alter its
binding characteristics in response to environmental changes en-
countered within a host during the course of an infection (22). In
this context, although FdeC may share functional homology with
other adhesins localized on the E. coli surface, its host cell-
dependentexpressionsuggestsaspeciﬁcroleduringcolonization.
Nevertheless,wealsoobservedthatinvitroconstitutiveexpression
of the protein is associated with an increased aggregative pheno-
type.WethereforesuggestthattheexpressionofFdeCatthesiteof
colonizationmaycontributetotheformationofmacrocolonies,a
phenotypeoftenassociatedwithE.coliinfections.Thisisinagree-
ment with our observation that fdeC mutant bacteria are attenu-
ated for bladder colonization during cochallenge experiments,
conﬁrming that FdeC is a virulence factor in mice. In fact, in vivo
competitionexperimentsbetweenwild-typeuropathogenicE.coli
and its fdeC mutant strain revealed that the loss of FdeC caused a
signiﬁcant ﬁtness defect during extraintestinal colonization.
We recently described FdeC (ECOK1_0290) as a promising
vaccine candidate against ExPEC infections (10). In vivo protec-
tion was evaluated in mice by subcutaneous injection of the puri-
ﬁed recombinant antigen followed by intraperitoneal challenge
with the E. coli pathogenic strain IHE3034. Using this model, we
found a good correlation between mortality and the bacterial
counts in the blood, with a signiﬁcant, although rather low, pro-
tectiveefﬁcacycomparedtothecontrolgroup.Basedonthefunc-
tional properties of FdeC, we hypothesized that the antigen may
exert a more efﬁcacious protective role in an experimental UTI
model.Indeed,wefoundthatintranasalimmunizationwithFdeC
provided considerable protection against experimental infection
with two different UPEC strains. Of interest, site-speciﬁc protec-
tionwasobserved,asmiceimmunizedwiththeFdeCproteinwere
signiﬁcantly protected from strain 536 colonization only in the
kidney,witha1.5-logreductioninthemedianCFU/gtissueand
more than 50% of mice having undetectable levels of bacteria in
that organ. Surprisingly, despite the signiﬁcant protection in the
FIG 7 FdeCB prevents the spread of UPEC infection into the kidney. Mice were immunized intranasally with a 10:1 ratio of FdeCB to CT containing 100 go f
FdeCB or with 10 g CT alone (mock immunized). After two boosts of 25 g antigen (10:1 ratio of antigen to CT) or CT alone given on days 7 and 14, the
individual mice were transurethrally challenged with 108 CFU of UPEC strain 536 (A) and CFT073 (B). After 48 h, bladder and kidneys were harvested and
homogenized. Bacteria in urine and in the tissue homogenates were enumerated by plating serial dilutions. Symbols represent CFU/g tissue or CFU/ml urine of
individual mice, and bars indicate median values. P values were determined using the nonparametric Mann-Whitney signiﬁcance test.
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level of bacteria able to colonize the bladder.
The evidence reported in this study indicates that functional
characterization of potential vaccine candidates, and determina-
tionoftheirroleinpathogenesis,maybepivotaltounderstanding
the basis for inducing protective immunity during speciﬁc stages
of disease and support the development of more efﬁcacious vac-
cines.
MATERIALS AND METHODS
Ethics statement. All procedures were conducted according to protocol
08999 approved by the University Committee on the Care and Use of
Animals at the University of Michigan Medical School. The approved
proceduresareincompliancewithuniversityguidelines,stateandfederal
regulations, and the standards of the Guide for the Care and Use of Labo-
ratory Animals.
Bacterial strains and culture conditions. ExPEC strain IHE3034 (se-
rotype O18: K1:H7), isolated in Finland in 1976 from a case of human
neonatal meningitis (23); RS218 (serotype O18:K1:H7); 536 (serotype
O6:K15:H31) (24); CFT073 (serotype O6:K2:H1) (25); MG1655 (K-12)
(26);andW3110(K-12)(27)wereusedforcomparativegenomeanalysis.
BacteriawereculturedinLuria-Bertani(LB)liquidmediumoragarplates
at 37°C. E. coli DH5 was used for cloning purposes, and E. coli
BL21(DE3) was used for expression of His-tagged fusion proteins. The
clones carrying a speciﬁc cassette conferring antibiotic resistance were
grown in the presence of ampicillin (100 g/ml) or kanamycin (50 g/
ml).
Crystallizationanddatacollection.Crystallizationexperimentswere
performed in Greiner 96-well low-proﬁle sitting-drop plates. Initial
screen conditions consisted of a sparse matrix of 480 conditions set up at
4°C and 20°C (28, 29). The reservoir volume was 50 l, and the drop
consistedof200nlproteinwithanequalvolumeofprecipitant.Promising
proteincrystalstookover4monthstogrowunderaconditioncontaining
20%polyethyleneglycol6000(PEG6000)in0.1MBicinebufferatpH9.0.
Crystalswereloopedandchilledatliquidnitrogentemperature.Cryopro-
tection was achieved via the addition of 20% glycerol solution to the
mother liquor prior to harvesting the crystal. Data were collected at the
Advanced Light Source (ALS; Berkeley) on beamline 5.0.2. Data were
reducedusingHKL2000andtheCCP4suite(30).Datareductionstatistics
are presented in Table 2.
Structure solution and reﬁnement. The structure was solved by mo-
lecular replacement using the program Phaser (31) and an ensemble of
individual immunoglobulin domains from the homologues invasin and
intimin(PDBIDs1CWVand1F00,respectively)asprobemoleculeswith
all data to 2.5 Å. Full-length probes of invasin and intimin failed to pro-
duce expectable solutions, in initial runs. In all the positions and orienta-
tions of three immunoglobulin domains found via this method, packing
considerations made it clear that the fourth domain, believed to be in the
construct,wasmissinginthecrystalstructure,whichcontainedonly36%
solvent with the 3 domains ﬁtted. Iterative rounds of building and reﬁne-
ment with Buster (32) and Coot (33) produced a structure whose reﬁne-
ment converged with excellent geometry (data and reﬁnement statistics
are shown in Table 2). Superposition with structural homologues was
performed with Coot and SSM (33, 34). All crystallographic manipula-
tions other than those stated used the CCP4 package (30).
Binding assay using puriﬁed protein. Approximately 2  105 cells
were incubated with increasing concentrations of recombinant protein
for1hat4°C.Cellswerethenincubatedwithrabbitpolyclonalanti-FdeC
serum. Subsequently, cells were incubated with a goat anti-rabbit IgG
ﬂuorescein isothiocyanate (FITC)-conjugated antibody (Jackson Immu-
noResearch Laboratories). FACS acquisition was performed using a
ﬂuorescence-activatedcellsorter(BectonDickinson).Datawereanalyzed
using FlowJo software.
Confocal microscopy analysis of E. coli strains adhering to eukary-
otic cells and tissues. Epithelial cells were grown to conﬂuence and in-
fected with E. coli strains at a multiplicity of infection of 10:1 for different
time points. Samples were washed and ﬁxed in 3% paraformaldehyde
(PFA) for 15 min at room temperature (RT). After 2 h of blocking in 1%
bovine serum albumin (BSA), the rabbit anti-FdeC serum was used to
detect the protein, using a donkey anti-rabbit IgG Rhodamine Red
X-conjugated antibody as secondary antibody. Alexa Fluor dye-labeled
phalloidins(Invitrogen)wereusedtostaintheactincytoskeletonaccord-
ing to the manufacturer’s instructions. Bacterial and cellular DNA were
stained with 4=,6-diamidino-2-phenylindole (DAPI). The ProLong Gold
reagent(Invitrogen)wasusedasaliquidmountant.TheW3110strainwas
detected using the polyclonal rabbit anti-E. coli K-12 (Dako) and the
Alexa-Fluor 488 goat anti-rabbit IgG secondary antibody. The analysis
was done with a Zeiss LSM 710 laser scanning microscope. Confocal im-
agingontissueswasperformedonbladdersectionsderivedfromExPEC-
infected animals. In detail, the bladder was cut transversely, preserved in
10% formalin (pH 7.2), and embedded in parafﬁn. Tissue sections were
cut and mounted onto slides. Samples were dewaxed and subjected to
antigen retrieval before the immunoﬂuorescence labeling. Staining of the
sections was done as described for in vitro staining, except for tissues that
were labeled with wheat germ agglutinin (WGA) (Alexa Fluor 647 conju-
gated; Invitrogen).
Vaccination in a murine model of ascending UTI. Female CBA/J
mice, 6 to 8 weeks old, were transurethrally inoculated as previously de-
scribed(35).Puriﬁedantigenwasmixedwithcholeratoxin(CT)(Sigma)
at a ratio of 10:1. The vaccine was administered intranasally in a total
volumeof20l/animal(10l/nare).Animalsreceivedaprimarydoseon
day 0 of 100 g antigen (containing 10 g CT) or 10 g CT alone. Two
boosts of 25 g antigen (mixed with 2.5 g CT) or 2.5 g CT alone were
given on days 7 and 14, and mice were challenged on day 21. E. coli
CFT073 and 536 suspensions in phosphate-buffered saline (PBS) (50 l/
mouse) were delivered transurethrally using a sterile 0.28-mm-inner-
diameter polyethylene catheter connected to an infusion pump (Harvard
Apparatus), with a total inoculum of 108 CFU/mouse. For determination
ofCFU,organswereasepticallyremovedfromeuthanizedanimalsat48h
postinoculation and homogenized in PBS with a GLH homogenizer
(Omni International). Bacteria in tissue homogenates were enumerated
TABLE 2 Crystallographic and reﬁnement statistics
Parameter FdeC
Protein
Space group P21212
No. of molecules in ASUd 1
Unit cell (Å) 44.6, 150.93, 47.40
Wavelength (Å) 0.9202
Resolution (Å) 50.0-1.9
Total no. of unique reﬂections 24,734
Completeness, % (highest shell) 95.6 (67.0)
Rmerge, % (highest shell) 0.084 (0.634)
Highest-resolution shell, Å 1.97–1.90
Mean I/ (I) (highest shell) 23.9 (1.7)
Reﬁnement
No. of references, working set 23,413
No. of references, test set 1,265
Rcryst (Rfree
a)b (%) 17.1 (20.5)
RMSD bonds (Å) 0.017
RMSD angles (°) 1.44
Avg B (Å)2 26.27
ESUe based on Rfree (Å)c 0.135
a Rfree  as for Rcryst, but for 5.0% of the total reﬂections chosen at random and
omitted from reﬁnement.
b R factor  |Ii  Ii|| / |Ii|, where Ii is the scaled intensity of the ith measurement
and Ii is the mean intensity for that reﬂection.
c Estimated overall coordinate error.
d ASU, asymmetric unit.
e ESU, estimated standard uncertainty.
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4000 spiral plater (Spiral Biotech), and CFU were determined using a
QCountautomatedplatecounter(SpiralBiotech).Bloodwascollectedas
necessary from anesthetized mice by an infraorbital bleed using 1.1- to
1.2-mm Micro-Hematocrit capillary tubes (Fisher), and serum was sepa-
rated using Microtainer serum separator tubes (Becton Dickinson). The
animals were 15 weeks old at the conclusion of all experiments.
Protein structure accession number. The structure has been depos-
ited in the structure database of the Genomics Institute of the Novartis
ResearchFoundation(SanDiego,CA),andentrycodeintheProteinData
Bank (PDB) is 4E9L.
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